Association between moderate to severe atopic dermatitis and lifestyle factors in the Dutch general population.
Journal
Clinical and experimental dermatology
ISSN: 1365-2230
Titre abrégé: Clin Exp Dermatol
Pays: England
ID NLM: 7606847
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
accepted:
04
04
2022
pubmed:
7
4
2022
medline:
28
7
2022
entrez:
6
4
2022
Statut:
ppublish
Résumé
Studies on the association between severity of atopic dermatitis (AD) and lifestyle factors in adults have not been conducted in the Netherlands to date. To explore the association between moderate to severe AD and lifestyle factors in adults in the Dutch general population. We conducted this cross-sectional study within the Lifelines Cohort Study by sending a digital AD questionnaire to 135 950 adults in 2020. We extracted data on lifestyle factors from baseline, collected between 2006 and 2013. We analysed the association between lifestyle factors and presence of AD of any severity and of moderate to severe AD, using binary logistic regression and linear regression models. We enrolled 56 896 participants (mean age 55.8 years, 39.7% males). The lifetime prevalence of self-reported physician-diagnosed AD was 9.1%, and the point prevalence of any AD and of moderate to severe AD was 3.3% and 2.3%, respectively. We found that moderate to severe AD was associated with smoking habit of > 15 pack-years, alcohol consumption of > 2 drinks per day, chronic stress, Class I obesity, and both shorter and longer sleep duration. Moreover, we found dose-response associations with increases in smoking pack-years and level of chronic stress. We observed no associations with abdominal obesity, physical activity, diet quality or a vegetarian/vegan diet. We found associations between moderate to severe AD and some modifiable lifestyle factors. Our findings indicate that more screening and counselling for lifestyle factors, particularly smoking, alcohol use, stress, obesity and sleep disturbances, appears warranted in patients with moderate to severe AD. Further longitudinal studies are required to better characterize the direction of these associations and to develop strategies for prevention.
Sections du résumé
BACKGROUND
BACKGROUND
Studies on the association between severity of atopic dermatitis (AD) and lifestyle factors in adults have not been conducted in the Netherlands to date.
AIM
OBJECTIVE
To explore the association between moderate to severe AD and lifestyle factors in adults in the Dutch general population.
METHODS
METHODS
We conducted this cross-sectional study within the Lifelines Cohort Study by sending a digital AD questionnaire to 135 950 adults in 2020. We extracted data on lifestyle factors from baseline, collected between 2006 and 2013. We analysed the association between lifestyle factors and presence of AD of any severity and of moderate to severe AD, using binary logistic regression and linear regression models.
RESULTS
RESULTS
We enrolled 56 896 participants (mean age 55.8 years, 39.7% males). The lifetime prevalence of self-reported physician-diagnosed AD was 9.1%, and the point prevalence of any AD and of moderate to severe AD was 3.3% and 2.3%, respectively. We found that moderate to severe AD was associated with smoking habit of > 15 pack-years, alcohol consumption of > 2 drinks per day, chronic stress, Class I obesity, and both shorter and longer sleep duration. Moreover, we found dose-response associations with increases in smoking pack-years and level of chronic stress. We observed no associations with abdominal obesity, physical activity, diet quality or a vegetarian/vegan diet.
CONCLUSION
CONCLUSIONS
We found associations between moderate to severe AD and some modifiable lifestyle factors. Our findings indicate that more screening and counselling for lifestyle factors, particularly smoking, alcohol use, stress, obesity and sleep disturbances, appears warranted in patients with moderate to severe AD. Further longitudinal studies are required to better characterize the direction of these associations and to develop strategies for prevention.
Identifiants
pubmed: 35384028
doi: 10.1111/ced.15212
pmc: PMC9545670
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1523-1535Subventions
Organisme : China Scholarship Council
ID : 201806200089
Organisme : Novartis
Informations de copyright
© 2022 The Authors. Clinical and Experimental Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
Références
J Invest Dermatol. 2015 Jan;135(1):56-66
pubmed: 25078665
Allergy. 2017 May;72(5):783-791
pubmed: 27864954
J Invest Dermatol. 2016 Aug;136(8):1714-1716
pubmed: 27189827
Int J Environ Res Public Health. 2016 Jul 27;13(8):
pubmed: 27472355
Dermatol Res Pract. 2012;2012:403908
pubmed: 22969795
Br J Dermatol. 2019 Apr;180(4):821-827
pubmed: 29947106
J Invest Dermatol. 2017 Jan;137(1):26-30
pubmed: 27616422
Int J Epidemiol. 2015 Aug;44(4):1172-80
pubmed: 25502107
J Investig Allergol Clin Immunol. 2010;20(6):469-75
pubmed: 21243930
Eur J Clin Nutr. 2018 Aug;72(8):1111-1119
pubmed: 29895847
Allergy. 2012 Nov;67(11):1408-14
pubmed: 22943607
J Eur Acad Dermatol Venereol. 2019 Sep;33(9):1762-1767
pubmed: 31045273
J Allergy Clin Immunol. 2005 Jun;115(6):1109-17; quiz 1118
pubmed: 15940119
Contact Dermatitis. 2022 Feb;86(2):80-88
pubmed: 34766356
Br J Dermatol. 2021 May;184(5):871-879
pubmed: 33090454
Br J Dermatol. 2020 Jul;183(1):128-138
pubmed: 31630393
Med Sci Sports Exerc. 1993 Jan;25(1):71-80
pubmed: 8292105
Allergy. 2018 Jun;73(6):1284-1293
pubmed: 29319189
Am J Respir Crit Care Med. 2007 Apr 1;175(7):661-6
pubmed: 17234901
J Am Acad Dermatol. 2016 Dec;75(6):1119-1125.e1
pubmed: 27542586
Br J Dermatol. 2018 May;178(5):1111-1118
pubmed: 29247509
Ann Allergy Asthma Immunol. 2018 Nov;121(5):604-612.e3
pubmed: 30092266
Psychol Med. 2012 Dec;42(12):2599-608
pubmed: 22490940
Acta Derm Venereol. 2014 Mar;94(2):185-7
pubmed: 23994911
J Am Acad Dermatol. 2016 Sep;75(3):629-631
pubmed: 27543217
J Clin Epidemiol. 2003 Dec;56(12):1163-9
pubmed: 14680666
J Eur Acad Dermatol Venereol. 2018 Aug;32(8):1238-1245
pubmed: 29377395
J Am Acad Dermatol. 2008 Mar;58(3):415-20
pubmed: 18280338
Br J Dermatol. 2013 Dec;169(6):1326-32
pubmed: 24024631
J Eur Acad Dermatol Venereol. 2021 Nov;35(11):e787-e790
pubmed: 34161629
J Am Acad Dermatol. 2015 Apr;72(4):606-16.e4
pubmed: 25773409
J Allergy Clin Immunol. 2015 Mar;135(3):721-8.e6
pubmed: 25579484